Value through Innovation27 July 2016

Clinical Study Results

  • Hyaluronic acid - Osteoarthritis
    Clinical Study Number 1139.4
    Study Indication Osteoarthritis
    Product Hyaluronic acid
    Generic Name Hyaluronic acid
    Lab Code
    Clinical Phase IV
    Study Title

    A multicentre, open-label and randomised clinical trial to compare inpatient with knee osteoarthritis the medicoeconomic benefits as well as effectiveness and safety of Synvisc® versus usual treatments

    Study Document Trial synopsis 1139.4 english
  • Hyaluronic acid - Osteoarthritis
    Clinical Study Number 1139.5
    Study Indication Osteoarthritis
    Product Hyaluronic acid
    Generic Name Hyaluronic acid
    Lab Code
    Clinical Phase IV
    Study Title

    Use of SYNVISC in knee osteoarthritis. Survey on practice. "U.S.A.G.E.Pratique"

    Study Document Trial synopsis 1139.5 english
  • MOBIC ® - Osteoarthritis
    Clinical Study Number 107.264
    Study Indication Osteoarthritis
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase IV
    Study Title

    Clinical therapeutic evaluation program in patients with osteomuscular diseases.

    Study Document Trial synopsis 107.264_CO english
  • MOBIC ® - Osteoarthritis
    Clinical Study Number 107.265
    Study Indication Osteoarthritis
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase III
    Study Title

    A randomised, open-labelled study to compare the efficacy and safety of meloxicam 7.5 mg IM ampoules once daily and meloxicam 7.5 mg tablets administered orally once daily over a period of 7 days in patients with osteoarthritis (OA).

    Study Document Trial synopsis 107.265_CO english
  • MOBIC ® - Osteoarthritis
    Clinical Study Number 107.273
    Study Indication Osteoarthritis
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase IV
    Study Title

    Assessing the impact of MOVALIS® on Health Related Quality of Life

    Study Document Trial synopsis 107.273 english
  • MOBIC ® - Osteoarthritis
    Clinical Study Number 107.229
    Study Indication Osteoarthritis
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase IV
    Study Title

    Open label study to assess the efficacy and safety of meloxicam 7.5mg vs. diclofenac 100 mg SR in patients with osteoarthritis of the knee

    Study Document Trial synopsis 107.229_CO english
  • MOBIC ® - Osteoarthritis
    Clinical Study Number 107.228
    Study Indication Osteoarthritis
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase IV
    Study Title

    Open study to assess the efficacy and safety of meloxicam 7.5mg in patients with osteoarthritis of the knee

    Study Document Trial synopsis 107.228_CO english
  • MOBIC ® - Osteoarthritis
    Clinical Study Number 107.210
    Study Indication Osteoarthritis
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase IIIb
    Study Title

    A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients with Osteoarthritis of the Hip, Knee, Hand or Spine

    Study Document Trial synopsis 107.210 english
  • MOBIC ® - Osteoarthritis
    Clinical Study Number 107.270
    Study Indication Osteoarthritis
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase IV
    Study Title

    Post Marketing Surveillance to assess the safety and efficacy of Mobic® (meloxicam) intramuscular injection (7.5mg ~ 15mg, q.d.) up to 3 days (in case of need for prolonged treatment, switch to Mobic® capsule therapy was possible) in Korean patients with osteoarthritis and rheumatoid arthritis (KFDA regulatory requirement PMS)

    Study Document Trial synopsis 107.270 english
  • BI 1026706 - Osteoarthritis
    Clinical Study Number 1320.2
    Study Indication Healthy ; Osteoarthritis
    Product BI 1026706
    Generic Name BI 1026706
    Lab Code BI 1026706
    Clinical Phase I
    Study Title

    Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple rising oral doses of BI 1026706 in male and female healthy subjects and patients with osteoarthritis of the knee (randomised, double-blind, placebo-controlled within the dose groups, clinical phase I)

    Study Document Trial synopsis 1320.2 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.